Diabetic foot ulcers are considered a major complication of diabetes mellitus, and probably the major component of diabetic foot syndrome. Diabetic foot ulcers have a considerable negative impact on patients’ lives, and are highly susceptible to infection, leading all too often to amputation. Diabetic foot ulcers represent a huge risk to a patient’s quality of life, escalating wound/infection management and costs, and accounting for a large proportion of all national healthcare budgets.
Diabetes is one of the serious chronic diseases that need attention. According to a research article by Bakker et al, it is estimated that approximately 15% of all people with diabetes will be affected by a foot ulcer during their lifetime, and, in fact, 1 in 4 people with diabetes will develop at least one ulcer post-diagnosis. All these factors are contributing to the impact of diabetic nephropathy, across the globe.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence